Control of arthritis pain with anti-nerve-growth factor: Risk and benefit

Current Rheumatology Reports

Volumn 14, Issue 6, 2012, Pages 583-588

  Seidel, Matthias F ^a   Lane, Nancy E ^b  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antagonists; Arthritis; Benefit; Nerve growth factor; Neurogenic inflammation; NGF; Pain; Receptor antagonists; Rheumaticdiseases; Risk

Indexed keywords

ANTINOCICEPTIVE AGENT; BONE MORPHOGENETIC PROTEIN 2; CALCITONIN GENE RELATED PEPTIDE; CELECOXIB; DICLOFENAC; FASINUMAB; FULRANUMAB; K 252A; MEDI 578; MNAC 13; MONOCLONAL ANTIBODY NGF30; MUMAB 911; N (2 HYDROXYETHYLAMINO) 3 NITRONAPHTHALIMIDE; NAPROXEN; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR ANTAGONIST; NERVE GROWTH FACTOR RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; PG 110; PLACEBO; SEROTONIN; SUBSTANCE P; TANEZUMAB; UNCLASSIFIED DRUG;

ABNORMAL SENSATION; ALLODYNIA; ARTHRALGIA; ARTHRITIS; ARTICLE; AUTOIMMUNITY; BACKACHE; BACTERIAL CELLULITIS; BONE NECROSIS; BONE PAIN; BREAST CANCER; CARDIOVASCULAR DISEASE; CARPAL TUNNEL SYNDROME; CELLULITIS; CHRONIC PANCREATITIS; CHRONIC PROSTATITIS; COLLAGEN DISEASE; CONSTIPATION; CORNEA ULCER; CORONARY ARTERY DISEASE; DIABETIC NEUROPATHY; DIABETIC ULCER; DRUG EFFICACY; DRUG INDUCED HEADACHE; DYSESTHESIA; EDEMA; FALLING; FRACTURE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HIP OSTEOARTHRITIS; HUMAN; HYPERALGESIA; HYPERESTHESIA; HYPERTENSION; HYPESTHESIA; INFLAMMATION; INTERSTITIAL CYSTITIS; JOINT SWELLING; KNEE OSTEOARTHRITIS; LIMB PAIN; LOW BACK PAIN; LUNG EMBOLISM; MYALGIA; NAUSEA; NOCICEPTION; NONHUMAN; OSTEOARTHRITIS; PAIN; PARESTHESIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; POSTHERPETIC NEURALGIA; PROTEIN EXPRESSION; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; RISK BENEFIT ANALYSIS; SCLERITIS; SIDE EFFECT; SKIN ULCER; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX PAIN; ULCER; UPREGULATION; URINARY TRACT INFECTION;

ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS; HUMANS; NERVE GROWTH FACTOR; NEUROGENIC INFLAMMATION; NOCICEPTIVE PAIN; PAIN; RECEPTORS, NERVE GROWTH FACTOR;

EID: 84869186227     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-012-0289-8     Document Type: Article

References (63)

1. Riedel W, Neeck G. Nociception, pain, and antinociception: current concepts. Z Rheumatol. 2001; 60(6): 404-15. (Pubitemid 34066644)
2. Seidel M, Tsalik J, Vetter H, Mü ller W. Substance P in rheumatic diseases. Curr Rheum Rev. 2007; 3: 17-30. (Pubitemid 46603431)
3. Regoli D, Boudon A, Fauchere J. Receptors and antagonists for substance P and related peptides. Pharmacol Rev. 1994; 46(4): 551-99.
4. Hartung HP, Toyka KV. Activation of macrophages by substance P: induction of oxidative burst and thromboxane release. Eur J Pharmacol. 1983; 89(3-4): 301-5. (Pubitemid 13095876)
5. Hafströ m I, Gyllenhammar H, Palmblad J, Ringertz B. Substance P activates and modulates neutrophil oxidative metabolism and aggregation. J Rheumatol. 1989; 16(8): 1033-7. (Pubitemid 19234728)
6. Nakagawa N, Sano H, Iwamoto I. Substance P induces the expression of intercellular adhesion molecule-1 on vascular endothelial cells and enhances neutrophil ransendothelial migration. Peptides. 1995; 16(4): 721-5.
7. Payan DG, Brewster DR, Goetzl EJ. Specific stimulation of human T lymphocytes by substance P. J Immunol. 1983; 131(4): 1613-5. (Pubitemid 13010122)
8. Reinhardt RR, Laub JB, Fricke JR, et al. Comparison of neurokinin-1 antagonist, L-745,030, to placebo, acetominophen and ibuprofen in the dental pain model. Clin Pharmacol Ther. 1998; 63(2): 168.
9. Kushnir-Sukhov NM, Brown JM, Wu Y, et al. Human mast cells are capable of serotonin synthesis and release. J Allergy Clin Immunol. 2007; 119(2): 498-9. (Pubitemid 46204791)
10. Tominaga K, Alstergren P, Kurita H, Kopp S. Serotonin in an antigen-induced arthritis of the rabbit temporomandibular joint. Arch Oral Biol. 1999; 44: 595-601. (Pubitemid 29289238)
11. Harbuz MS, Perveen-Gill Z, Lalies MD, et al. The role of endogenous serotonin in adjuvant-induced arthritis in the rat. Br J Rheumatol. 1996; 35(2): 112-6.
12. Seidel MF, Mü ller W. Differential pharmacotherapy for subgroups of fibromyalgia patients with specific consideration of 5-HT3 receptor antagonists. Exp Opin Pharm. 2011; 12(9): 1381-91.
13. Seidel MF. Local injections of serotonin type-3 receptor antagonists as a therapeutic option in rheumatology. Fut Med Chem. 2012; 4(6): 705-7.
14. Liu L, Shenoy M, Pasricha PJ. Substance P and calcitonin gene related peptide mediate pain in chronic pancreatitis and their expression is driven by nerve-growth factor. JOP. 2011; 12(4): 389-94.
15. Horigome K, Pryor JC, Bullock ED, Johnson Jr EM. Mediator release from mast cells by nerve-growth factor, neurotrophin specificity and receptor mediation. J Biol Chem. 1993; 268 (20): 14881-7. (Pubitemid 23206634)
16. Gerber RK, Nie H, Arendt-Nielsen L, et al. Local pain and spreading hyperalgesia induced by intramuscular injection of nervegrowth factor are not reduced by local anesthesia of the muscle. Clin J Pain. 2011; 27(3): 240-7.
17. Levi-Montalcini R, Hamburger V. Selective growth stimulating effects of mouse sarcoma on the sensory and sympathetic nervous system of the chick embryo. J Exp Zool. 1951; 116(2): 321-61.
18. Barbacid M. Structural and functional properties of the TRK family of neurotrophin receptors. Ann N Y Acad Sci. 1995; 7 (766): 442-58. (Pubitemid 26169124)
19. Gruss HJ, Dower SK. The TNF ligand superfamily and its relevance for human diseases. Cytokines Mol Ther. 1995; 1(2): 75-105.
20. Seidel MF, Herguijuela M, Forkert R, Otten U. Nerve-growth factor in rheumatic diseases. Sem Arthr Rheum. 2009; 40(2): 109-26. This article summarizes the background and most important studies on NGF in rheumatic diseases.
21. Otten U, Ehrhard P, Peck R. Nerve-growth factor induces growth and differentiation of human B lymphocytes. Proc Natl Acad Sci USA. 1989; 86: 10059-63. (Pubitemid 20030775)
22. Nassenstein C, Mö hring UH, Luttmann W, et al. Differential expression of the neurotrophin receptors p75NTR, TrkA, TrkB and TrkC in human peripheral blood mononuclear cells. Exp Toxicol Pathol. 2006; 57 Suppl 2: 55-63. (Pubitemid 43766073)
23. Bischoff SC, Dahinden CA. Effect of nerve-growth factor on the release of inflammatory mediators by mature human basophils. Blood. 1992; 79(10): 2662-9.
24. Takafuji S, Bischoff SC, De Weck AL, Dahinden CA. Opposing effects of tumor necrosis factor-α and nerve-growth factor upon leukotriene C4 production by human eosinophils triggered with Nformyl- methionyl-leucyl- phenylalanine. Eur J Immunol. 1992; 22 (4): 969-74.
25. Gee AP, Boyle MD, Munger KL, et al. Nerve-growth factor: stimulation of polymorphonuclear leukocyte chemotaxis in vitro. Proc Natl Acad Sci USA. 1983; 80(23): 7215-8. (Pubitemid 14208829)
26. Cirulli F, Alleva E. The NGF saga: from animal models of psychosocial stress to stress-related psychopathology. Front Neuroendocrinol. 2009; 30(3): 379-95.
27. Cirulli F, Francia N, Branchi I, et al. Changes in plasma levels of BDNF and NGF reveal a gender-selective vulnerability to early adversity in rhesus macaques. Psychoneuroendocrin. 2009; 34: 172-80.
28. Aloe L, Alleva E, Bö hm A, Levi-Montalcini R. Aggressive behaviour induces release of nerve-growth factor from mouse salivary gland into the bloodstream. Proc Natl Acad Sci USA. 1986; 83 (16): 6184-7. (Pubitemid 16000677)
29. Aloe L, Bracci-Laudiero L, Alleva E, et al. Emotional stress induced by parachute jumping enhances blood nerve-growth factor levels and the distribution of nerve-growth factor receptors in lymphocytes. Proc Natl Acad Sci USA. 1994; 91: 10440-4. (Pubitemid 24329013)
30. Aloe L, Tuveri M, Guerra G, et al. Changes in human plasma nerve-growth factor level after chronic alcohol consumption and withdrawal. Alcohol Clin Exp Res. 1996; 20(3): 462-5. (Pubitemid 26150712)
31. Hefti FF, Rosenthal A, Walicke PA, et al. Novel class of pain drugs based on antagonism of NGF. Trends Pharmacol Sci. 2006; 27 (2): 85-91. (Pubitemid 43184029)
32. Lane NE, Schnitzer TJ, Birbara CA, et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med. 2010; 363(16): 1521-31. This study shows the efficacy of NGF antagonists on osteoarthritic pain.
33. Katz N, Borenstein DG, Birbara C, et al. Efficacy and safety of tanezumab in the treatment of chronic low-back pain. Pain. 2011; 152(10): 2248-58. This study shows the efficacy of NGF antagonists on low-back pain.
34. Schnitzer TJ, Lane NE, Birbara C, et al. Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain. Osteoarthr Cart. 2011; 19(6): 639-46.
35. Nagashima H, Suzuki M, Araki S, Tanezumab Investigators. Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebocontrolled study. Osteoarthr Cart. 2011; 19(12): 1405-12.
36. Tiseo P, Kivitz AJ, Ervin JE, et al. REGN475/SAR164877, a nerve growth factor inhibitor, in osteoarthritis patients with moderate to severe knee pain: results of a phase 2, randomized, double-blind, placebo-controlled study. Arthr Rheum. 2010; 62 Suppl 10: 710.
37. Feist E, Balanescu A, Wolfram G, et al. Efficacy and safety of tanezumab added on to diclofenac in patients with knee or hip osteoarthritis (NCT00864097). Arthr Rheum. 2011; 63 Suppl 10: 1096.
38. Yazici Y, Ekman EF, Greenberg HS, et al. Efficacy of tanezumab compared with non-steroidal anti-inflammatory drugs in patients with knee or hip osteoarthritis (NCT00809354). Arthr Rheum. 2011; 63 Suppl 10: 828.
39. Apfel SC, Arezzo JC, Brownlee M, et al. Nerve-growth factor administration protects against experimental diabetic sensory neuropathy. Brain Res. 1994; 634(1): 7-12. (Pubitemid 24013540)
40. Ding J, Cheng Y, Gao S, Chen J. Effects of nerve-growth factor and Noggin-modified bone marrow stromal cells on stroke in rats. J Neurosci Res. 2011; 89(2): 222-30.
41. Lecht S, Arien-Zakay H, Marcinkiewicz C, et al. Nerve-growth factor-induced protection of brain capillary endothelial cells exposed to oxygen-glucose deprivation involves attenuation of Erk phosphorylation. J Mol Neurosci. 2010; 41(1): 183-92.
42. Liberini P, Cuello AC. Effects of nerve-growth factor in primate models of neurodegeneration: potential relevance in clinical neurology. Rev Neurosci. 1994; 5(2): 89-104. (Pubitemid 24231040)
43. Scott SA, Crutcher KA. Nerve-growth factor and Alzheimer's disease. Rev Neurosci. 1994; 5(3): 179-211.
44. Colafrancesco V, Villoslada P. Targeting NGF pathway for developing neuroprotective therapies for multiple sclerosis and other neurological diseases. Arch Ital Biol. 2011; 149(2): 183-92.
45. Ghilardi JR, Freeman KT, Jimenez-Andrade JM et al. Neuroplasticity of sensory and sympathetic nerve fibers in the painful arthritic joint. Arthr Rheum 2012; in press.
46. Pincelli C, Sevignani C, Manfredini R, et al. Expression and function of nerve-growth factor and nerve-growth factor receptor on cultured keratinocytes. J Invest Dermatol. 1994; 103(1): 13-8. (Pubitemid 24227562)
47. Lambiase A, Rama P, Bonini S, et al. Topical treatment with nervegrowth factor for corneal neurotrophic ulcers. N Engl J Med. 1998; 338(17): 1174-80. (Pubitemid 28180745)
48. Lambiase A, Bonini S, Micera A, et al. Expression of nervegrowth factor receptors on the ocular surface in healthy subjects and during manifestation of inflammatory diseases. Invest Ophthalmol Vis Sci. 1998; 39(7): 1272-5. (Pubitemid 28247365)
49. Tuveri MA, Generini S, Matucci-Cerinic M, Aloe L. NGF, a useful tool in the treatment of chronic vasculitic ulcers in rheumatoid arthritis. Lancet. 2000; 356: 1739-40.
50. Aloe L. Nerve-growth factor, human skin ulcers and vascularization. Our experience. Prog Brain Res. 2004; 146: 515-22. (Pubitemid 37541402)
51. Sensebe L, Deschaseaux M, Li J, et al. The broad spectrum of cytokine gene expression by myoid cells from the human marrow microenvironment. Stem Cells. 1997; 15(2): 133-43. (Pubitemid 27152521)
52. Labouyrie E, Dubus P, Groppi A, et al. Expression of neurotrophins and their receptors in human bone marrow. Am J Pathol. 1999; 154(2): 405-15. (Pubitemid 29094091)
53. Aiga A, Asaumi K, LeeYJ, et al. Expression of neurotrophins and their receptors tropomyosin-related kinases (Trk) under tension-stress during distraction osteogenesis. Acta Med Okayama. 2006; 60(5): 267-77. (Pubitemid 46142094)
54. Yan XZ, Ge SH, Sun QF, et al. A pilot study evaluating the effect of recombinant human bone morphogenetic protein-2 and recombinant human beta-nerve-growth factor on the healing of class III furcation defects in dogs. J Periodontol. 2010; 81(9): 1289-98.
55. Letic-Gavrilovic A, Piattelli A, Abe K. Nerve-growth factor beta (NGF beta) delivery via a collagen/hydroxyapatite (Col/HAp) composite and its effects on new bone ingrowth. J Mater Sci Mater Med. 2003; 14(2): 95-102. (Pubitemid 36337562)
56. Mammoto T, Seerattan RA, Paulson KD, et al. Nerve-growth factor improves ligament healing. J Orthop Res. 2008; 26(7): 957-64.
57. Koewler NJ, Freeman KT, Buus RJ, et al. Effects of a monoclonal antibody raised against nerve-growth factor on skeletal pain and bone healing after fracture of the C57BL/6J mouse femur. J Bone Miner Res. 2007; 22(11): 1732-42. (Pubitemid 351235139)
58. Gaš perš ic R, Kovacic U, Glisovic S, et al. Anti-NGF treatment reduces bone resorption in periodontitis. J Dent Res. 2010; 89(5): 515-20.
59. Della Torre P, Picuti G, Di Filippo P. Rapidly progressive osteoarthritis of the hip. Ital J Orthop Traumatol. 1987; 13(2): 187-200.
60. Scuri M, Samsell L, Piedimonte G. The role of neurotrophins in inflammation and allergy. Inflamm Allergy Drug Targets. 2010; 9 (3): 173-80.
61. Zhu ZW, Friess H, Wang L, et al. Nerve-growth factor exerts differential effects on the growth of human pancreatic cancer cells. Clin Cancer Res. 2001; 7(1): 105-12. (Pubitemid 32110212)
62. Jin H, Pan Y, Zhao L, et al. p75 neurotrophin receptor suppresses the proliferation of human gastric cancer cells. Neoplasia. 2007; 9 (6): 471-8. (Pubitemid 46983449)
63. Goda M, Atagi S, Amitani K, et al. Nerve-growth factor suppresses prostate tumor growth. J Pharmacol Sci. 2010; 112(4): 463-6.